AbbVie UK
AbbVie UK is the UK subsidiary of AbbVie Inc., commercialising and clinically developing reimbursed prescription medicines across five therapeutic areas, namely immunology, oncology, neuroscience, eye care, and Allergan Aesthetics, through NHS distribution channels, with approximately 1,200 employees across four UK sites.
- Company typePrivate
- Founded2013
- HeadquartersLondon, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What AbbVie UK does
AbbVie UK is the UK operating subsidiary of AbbVie Inc., a global research-driven biopharmaceutical company. It is incorporated as AbbVie Ltd, a private limited company in England and Wales, with its registered headquarters in Maidenhead, Berkshire, and approximately 1,200 employees distributed across four UK sites in Maidenhead, Marlow, Oxford (discovery facility), and Sittingbourne. The UK operation is responsible for commercialising and clinically developing AbbVie's medicines within the National Health Service across five therapeutic areas: immunology (rheumatology, dermatology, gastroenterology), oncology (blood cancers and solid tumours), neuroscience (Parkinson's, Alzheimer's, migraine, schizophrenia, stroke), eye care, and medical aesthetics through the Allergan Aesthetics sub-brand.
The company's underlying technology platform spans small molecules, biologics, antibody-drug conjugates, targeted protein degraders, cell therapies, precision medicine, genetics and genomics, and artificial intelligence and machine learning applied end-to-end across R&D. Approximately 50 new molecular entities and 90+ compounds or indications sit in the pipeline globally, with 75% of AbbVie's medicines classified as first-in-kind, and 403 active UK clinical trial sites supporting 83 active trials and 1,470 enrolled patients as of 2026. The Allergan Aesthetics portfolio (acquired in 2020) provides a separate medical-aesthetics commercialisation channel.
AbbVie UK generates revenue by selling reimbursed prescription medicines through NHS pathways, complemented by enterprise field sales engagement with NHS trusts and healthcare professionals across the UK. Recent 2026 launches include AQUIPTA (atogepant) for acute migraine and ELAHERE (mirvetuximab soravtansine) for ovarian cancer. Distribution is direct via a UK sales force targeting NHS commissioning bodies, hospitals, and prescribers, with multi-channel marketing via corporate website, LinkedIn, YouTube, clinical trial registries, and ABPI-compliant medical information communications. Strategic NHS collaborative working partnerships span dermatology, immunology, gastroenterology, neuroscience, and ophthalmology across multiple NHS Foundation Trusts.
AbbVie UK firmographics
Firmographics- Name
- AbbVie UK
- Legal name
- AbbVie Ltd
- Website
- https://abbvie.co.uk
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AbbVie UK is the UK subsidiary of AbbVie Inc., commercialising and clinically developing reimbursed prescription medicines across five therapeutic areas, namely immunology, oncology, neuroscience, eye care, and Allergan Aesthetics, through NHS distribution channels, with approximately 1,200 employees across four UK sites.
- Ownership category
- akta.pro rank
AbbVie UK industry classification
Industry- Product category
- Pharmaceutical Medicines
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where AbbVie UK is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices4 records
Markets served
AbbVie UK business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Pharmaceutical Product Sales: AbbVie generates revenue through the discovery, development, and sale of innovative medicines. The company treats approximately 60 million people every year with its products across 175+ countries worldwide.
- Medical Aesthetics Products: Allergan Aesthetics, an AbbVie company, develops, manufactures and markets a portfolio of leading aesthetics brands and products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Pharmaceutical prescription medicines |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
AbbVie UK product offering
Product offeringCore offering
AbbVie UK discovers, develops, and commercialises innovative prescription medicines for patients in the United Kingdom across five core therapeutic areas. Its offering is centred on branded pharmaceutical products supplied to the NHS and to UK healthcare professionals, with pricing and access negotiated through NHS England and related UK payer frameworks.
Product overview
AbbVie UK is a global research-driven pharmaceutical company offering a diverse portfolio of innovative medicines across five core therapeutic areas: Immunology (rheumatology, dermatology, gastroenterology), Oncology (blood cancers and solid tumors), Neuroscience (neurological and psychiatric disorders), Eye Care, and Medical Aesthetics through the Allergan Aesthetics sub-brand. The company operates approximately 50 new molecular entities in development with 90+ compounds or indications in its pipeline, supported by R&D investment of $13.8 billion in 2025. UK operations include clinical development services with 403 active clinical trial sites and approximately 1,200 employees across four sites in Maidenhead, Marlow, Oxford, and Sittingbourne.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 75% of AbbVie medicines are considered first-in-kind
- +4 more outcomes
Companies that use AbbVie UK
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles1 record
AbbVie UK technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
AbbVie UK partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- Manchester NHS Foundation TrustcoreCollaborative working project in Dermatology focused on improving patient care pathways and health system efficiency. Executive summary available in document UK-IMMD-260005.
- The Northern Alliance NHS Foundation TrustcoreCollaborative working project (Project Catalyst) with Salford Pharmacy focused on improving patient care delivery.
- Barts NHS TrustcoreCollaborative working agreement in Immunology to improve patient outcomes and care pathways.
- Health Innovation Manchester (HInM)coreCollaborative working project (Migraine Pathway Transformation) in Neuroscience to improve migraine care pathways.
- Health Innovation North East and North Cumbria (HI NENC)coreCollaborative working project in Neuroscience to improve patient care pathways.
- Guys and St Thomas NHS Foundation TrustcoreCollaborative working project in Gastroenterology to improve patient care pathways.
- Royal Devon University Healthcare NHS Foundation TrustcoreCollaborative working project in Gastroenterology focused on improving patient outcomes.
- British Dermatology Nursing GroupminorCompleted collaborative working project including a National Dermatology Nurse Audit with outcome summary available.
- University Hospital Birmingham NHS Foundation TrustminorCompleted collaborative working project (Eyecare) with risk stratification and outcome summary documentation available.
- University Hospitals Coventry and Warwickshire NHS TrustminorCompleted collaborative working project (Project Catalyst - Rheumatology) with outcome summary documentation.
- Royal Wolverhampton NHS Trust (New Cross Hospital)coreCollaborative working project (Project Catalyst) in Gastroenterology focused on improving patient care delivery.
- Nonprofit Disaster Relief PartnersminorAbbVie partners with nonprofit organisations for disaster relief efforts including Ukraine support, Southern California Wildfires relief ($1M donation), Hurricane Helene and Milton relief ($250K donation), Israel and Gaza humanitarian response ($1M donation), Turkey and Syria earthquake relief ($1M donation), and Puerto Rico recovery ($100M five-year commitment).
- UK Charitable OrganisationscoreAbbVie has supported over 250 UK organisations since 2018 through its Grants, Donations and Charitable Contributions programme, supporting health, education, science or community-based projects.
- AbbVie FoundationcoreUS-based 501(c)(3) nonprofit working to drive transformative change in communities worldwide to help people live their healthiest life. Committed to advancing health equity through partnerships and employee impact programmes.
Scale indicators18 records
Recent moves6 records
Expansion highlights6 records
AbbVie UK competitors and assessment
Company assessmentDirect peers
- AstraZeneca: UK-headquartered global biopharmaceutical company with substantial UK R&D, manufacturing, and commercial operations spanning oncology, immunology, neuroscience, and respiratory—directly comparable as a major UK-based pharma with multi-therapeutic exposure competing for NHS market share.
- GSK: UK-headquartered global pharmaceutical and vaccines company with significant UK commercial and R&D footprint across specialty medicines, vaccines, and HIV—directly comparable in serving NHS channels and competing on immunology, oncology, and respiratory franchises.
Broad incumbents
- Pfizer: Global biopharmaceutical company with major UK operations across oncology, inflammation/immunology, vaccines, and internal medicine—comparable as a broad-incumbent pharma with deep NHS engagement and overlapping therapeutic portfolios.
- Novartis: Swiss-headquartered global pharmaceutical company with significant UK presence operating in oncology, immunology, neuroscience, and ophthalmology—overlaps AbbVie's therapeutic areas and competes for NHS reimbursement and clinical trial capacity.
- Roche: Swiss-headquartered global pharmaceutical company with substantial UK operations and R&D presence focused on oncology, immunology, ophthalmology, and neuroscience—directly comparable given parallel therapeutic area investments and NHS market participation.
- Merck (MSD): Global biopharmaceutical company (known as MSD in the UK) with significant UK oncology, vaccines, and specialty care operations—competes with AbbVie in oncology and immunology adjacencies and runs comparable UK clinical trial programs.
- Johnson & Johnson (Janssen): Global healthcare conglomerate with a large UK pharmaceutical subsidiary (Janssen) operating across oncology, immunology, neuroscience, and pulmonary hypertension—overlaps AbbVie's specialty care franchise and NHS commercial infrastructure.
- Sanofi: French-headquartered global biopharmaceutical company with UK operations across immunology (Dupixent), vaccines, rare disease, and oncology—competes with AbbVie in immunology specialty therapeutics and engages NHS through comparable market access channels.
- Eli Lilly: US-headquartered global pharmaceutical company with growing UK presence in oncology, immunology, neuroscience, and diabetes/obesity—competes with AbbVie in immunology and neuroscience while expanding UK R&D and manufacturing investments.
- Bristol-Myers Squibb: Global biopharmaceutical company with substantial UK commercial and clinical trial operations focused on oncology, immunology, and cardiovascular disease—overlaps AbbVie's specialty pharma footprint, particularly in hematology and immunology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
AbbVie UK social profiles
Digital presenceAbbVie UK financial estimates
Financial estimateRevenue estimate
Valuation estimate
AbbVie UK leadership team
Management profileNumber of profiles
AbbVie UK subsidiaries and ownership
Company hierarchySubsidiaries1 record
AbbVie UK funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AbbVie UK M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AbbVie UK
What does AbbVie UK do?
AbbVie UK discovers, develops, and commercialises innovative prescription medicines for patients in the United Kingdom across five core therapeutic areas. Its offering is centred on branded pharmaceutical products supplied to the NHS and to UK healthcare professionals, with pricing and access negotiated through NHS England and related UK payer frameworks.
Is AbbVie UK a public or private company?
AbbVie UK is a private company. It is classified as public and is currently operating.
When was AbbVie UK founded?
AbbVie UK was founded in 2013. It employs 101 to 250 people.
Where is AbbVie UK based?
AbbVie UK is headquartered in London, United Kingdom, in the Europe region.
How does AbbVie UK make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are medical Aesthetics Products.
Who are AbbVie UK's main competitors?
Direct peers on record are AstraZeneca and GSK. Broad incumbents are Pfizer, Novartis, Roche, Merck (MSD), Johnson & Johnson (Janssen), Sanofi, Eli Lilly and Bristol-Myers Squibb.
Does AbbVie UK have an API?
No public API is recorded for AbbVie UK.
What industry is AbbVie UK in?
AbbVie UK's product category is Pharmaceutical Medicines. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.